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Human African trypanosomiasis (HAT) is a fatal if untreated ﬂy-borne neuroinﬂammatory disease caused by protozoa of the
species Trypanosoma brucei (T.b.). The increasing trend of HAT cases has been reversed, but according to WHO experts, new
epidemics of this disease could appear. In addition, HAT is still a considerable burden for life quality and economy in 36 sub-
Saharan Africa countries with 15–20 million persons at risk. Following joined initiatives of WHO and private partners, the ﬁght
againstHATwasre-engaged,resultinginconsiderablebreakthrough.WepresentherewhatisknownatthisdayaboutHATetiology
and pathogenesis and the new insights in the development of accurate tools and tests for disease staging and severity monitoring in
the ﬁeld. Also, we elaborate herein the promising progresses made in the development of less toxic and more eﬃcient trypanocidal
drugs including the potential of medicinal plants and related alternative drug therapies.
1.Introduction
Human African trypanosomiasis (HAT) or sleeping sick-
ness is a severe ﬂy-borne disease caused by protozoan of
the species Trypanosoma brucei (T.b.). This disease was ﬁrst
described by European explorers by the late 1800s and
early 1900s even if this disease has probably existed in
Africa for many centuries [1]. The disease occurs in foci in
the tsetseﬂy(Glossinaspp)“belt”,avastgeographicalregion
ranging from the Sahara to the Kalahari Desert equivalent to
“the combined size of the United States, India and Western
Europe” where these ﬂies have their habitat [2–5]. Three
major epidemics of HAT occurred in Africa during the
last century, of which the most devastating (which killed
millions of persons) occurred from the 1930s to the 1960s
[6]. The colonial administrations established mobile teams
which systematically screened people in the endemic areas,
curing those found with the disease. This initiative resulted
in a signiﬁcant roll back of the disease. In the early 1960s,
HAT ceased to be a public health problem, and was no more
considered [7]. From the 1970s to the 1990s, favored by dra-
matic events such as wars and population movements, HAT
re-emergedand became anongoing epidemic. WHO,private
partners, and local governments took action, resulting in
a signiﬁcant decrease of the number of new cases reported
which,in2009,whichwaslowerthan10,000fortheﬁrsttime
in 50 years [6].
Despite these encouraging results, HAT is still a consid-
erable burden for life quality and economy in many sub-
Saharan Africa countries, where there may be 200 foci and
15–20 million persons at risk [8], as a large number of new
infections may remain unreported or undiagnosed because
of remote accessibility of many areas of the endemic region
and ongoing wars [9–11]. Besides, it is generally assumed
that new epidemics of HAT could occur, originating from
these uncontrolled areas where there still are very active
foci [12], as illustrated in Figure 1.H A Ta ﬀects poor and
remote rural populations dependent on agriculture, ﬁshing,2 The Scientiﬁc World Journal




(b) Countries at war from about 10 years
Figure 1: African trypanosomiasis repartition and sociopolitical instability. (a) Illustration of the geographical repartition of the countries
reporting the higher number of foci of both T.b. subspecies causing HAT. (b) Illustration of the geographical repartition of the countries at
war from more than 10 years. Note the correlation between countries at war and the localization of foci of T.b. gambiense.H A Tc a s e so c c u r
more often in countries with conﬂict, high political terror, or civil war, with a lag of about 10 years between the conﬂict beginning and peak
in incidence [12]. Epidemiological data are from [16].
or hunting. Until very recently, this disease was receiving
veryfewattention,andhealthinterventionsandresearchand
development were inadequate to the need [6]. In the last 50
years, only one drug, eﬂornithine, has been developed even
thoughahugeamountofknowledgeofAfricantrypanosome
biologyhasbeenaccumulatedinthemeantime[13].Overall,
the current drugs used to cure HAT are expensive, highly
toxic, need parenteral administration, and parasites increas-
ing resistance has been observed [14, 15]. Therefore, less
toxic, more eﬃcient, easy-to-administer and nonexpensive
drugs are urgently needed in the ﬁeld. WHO and some
private partners have been recently multiplying initiatives,
oﬀering funding for research activities for this purpose.
Some encouraging results have already been reported. The
research activities have been also aiming at developing new
ﬁeld suitable, easy to-use, and cheap tools to solve the HAT
diagnosis, staging, and follow-up issues observed in the
ﬁeld.
2.Diagnosis
HAT occurs in two forms: the Gambian or West African
form (caused by T.b. gambiense) and the Rhodesian or
East African form (caused by T.b. rhodesiense). The two
forms diﬀer in their clinical course, which is chronic (with
a course from months to years) in the Gambian form,
which represents about 95% of cases, and acute or subacute
(with a course from weeks to months) in the Rhodesian
form, which represents a minority of cases [7, 8]. After
infection and a relatively long (Gambian form) or short
(Rhodesian form) latency time, HAT evolves in two stages:
a hemolymphaticstage(ﬁrststageorstage1),whichdevelops
into a meningoencephalitic stage (second stage or stage
2) irreversibly followed by death if untreated [17, 18].
The hemolymphatic stage entails bouts of fever, headaches,
adenopathy, joint pains, and itching. The trypanosomes
proliferate at the site of infection and then spread to
the draininglymphaticnetworkandbloodstreamofthehost,
where they continuously multiply and from which they
invade the peripheral organs. Evidence from animal models
shows that at this stage of the disease, the parasites already
reside in the brain, but only in the structures located outside
the blood-brain barrier (BBB) such as circumventricular
organs [19]. The meningoencephalitic stage starts when the
trypanosomes cross the BBB and invade the central nervous
system parenchyma, excluding then the possibility to cure
patients with drugs used in the ﬁrst stage, as they do not
cross the BBB in amounts suﬃcient to kill the parasites.
The second stage is marked by a complex neuropsychiatric
syndrome characterized by changes of behavior, confusion,
sensory disturbances, poor coordination, a disruption of
the sleep-wake cycle, and an alteration of the sleep structure
[20, 21]. These qualitative alterations of sleep gave to HAT
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in use to cure the ﬁrst stage are relatively safe, the drugs
in use to cure the second stage are highly toxic, and
resulting undesired eﬀect include death in about 5% of cases
[21, 22].
In a general way, the clinical features of HAT do not
suﬃce for a precise diagnosis, and HAT is usually confused
with another endemic and more frequent sub-Saharan
Africa disease: malaria caused by the apicomplexan parasite
Plasmodium falciparum [23]. Therefore, For HAT diagnosis
in the ﬁeld, physical examination for posterior cervical
lymphadenopathy (Winterbottom’s sign) is performed, and
a venous blood sample is taken from the subjects [24].
The blood is screened for the presence of speciﬁc antibodies
against the parasite with the card agglutination test for
trypanosomiasis (CATT). CATT is used in the ﬁeld for mass
screening of HAT because of its sensitivity and ease of use
[24,25].However,CATTisnotspeciﬁc.False-positiveresults
have been reported in areas of low endemicity [26], and in
several foci in West Africa were found some T.b. gambiense
strains lacking the gene that encodes the surface glycoprotein
LiTat 1.3 [27], main gene targeted by the agglutination
process [28, 29]. To solve this problem, in addition to
CATT are performed microscopic examinations of lymph
aspirated from enlarged cervical lymph nodes or of blood
ﬁlms to assess the presence of the parasite in the lymph or
blood [30]. If the CATT remains positive at a dilution of
1i n8o rg r e a t e ra n dt r y p a n o s o m e sa r es e e ni nt h eb l o o d
ﬁlm (or lymph), the subject is diagnosed with HAT [31,
32]. However, the occurrence of cases with positive CATT
without parasites is common, and considering the high
toxicity of the trypanocidal drugs (even those used to cure
the ﬁrst stage), the management of such cases is debated and
constitutes an important issue [33]. Therefore, as possible
replacement of low sensitivity current parasite detection
methods has been suggested, molecular methods are far
more sensitive [33, 34].
Generally, T.b. gambiense loads in the blood are low,
and molecular methods request concentration techniques
to increase the detection of these parasites [25]. Such
techniquesincludecapillarytubecentrifugation,quantitative
buﬀycoat,andminianionexchangecentrifugationtechnique
(mAECT) [35, 36]. The latter was recently improved and is
the most sensitive technique for trypanosome detection of
the blood [37]. The mAECT technique consists in the sepa-
ration of trypanosomes by anion exchange chromatography
on diethylaminoethyl cellulose and low-speed centrifugation
to concentrate the eluted trypanosomes. The parasites can
then be detected by direct microscopic examination of
the sediment in a transparent collector tube [25, 33]. This
test presents the advantage of applicability in the ﬁeld
conditions and is robust and less cumbersome than previous
versions which required mounting a collector tube in water
formicroscopicexamination[38].However,the mainbottle-
neck and issues presented by this test as presently formulated
are the need of qualiﬁed personnel to perform it [39, 40], the
short-time stability (1 year maximum at 37◦C), as glucose is
incorporated in the column buﬀer [25], and the need of very
speciﬁc apparatus rarely found in the hospital of rural areas
where the disease is endemic [41].
AnotherattempttocharacterizetheHATstatusofCATT-
positive subjects is represented by the “immune trypanolysis
test,” a technique assessing the absence of nonspeciﬁc
trypanolytic activity in the plasma [26]. Studies evaluating
this technique were performed on plasma collected from
CATT-positive subjects with diverse epidemiological status
identiﬁedduringmedicalsurveysinGuinea,IvoryCoast,and
Burkina Faso HAT foci. This test appeared to be a marker
for contact with T.b. gambiense, suggesting its possible use as
a tool in the ﬁeld to identify nonparasitologically conﬁrmed
CATT-positivesubjectsaswellasthosewhohadcontactwith
T.b. gambiense a n ds h o u l db ef o l l o w e du p[ 26].
Also of interest are the polymerase chain reaction (PCR)
and nucleic acid sequence-based ampliﬁcation techniques
modiﬁed by coupling to oligochromatography for easy
and fast visualization of products [33]. These techniques
appeared to be very sensitive and speciﬁc for diagnosis of
T.b. gambiense in studies performed on blood samples from
DRC HAT patients. However, they failed to be as sensitive
and speciﬁc for T.b. rhodesiense detection on blood samples
from Uganda HAT patients [42].
Of high interest for the development of less invasive
HAT diagnosis tests are the encouraging results from studies
performed on saliva samples from T.b. gambiense HAT
patientsusingoptimizedtestformatsonthebasisofenzyme-
linked immunosorbent assay (ELISA) antibody detection
technique. As ELISAs performed on serum and CATT
performed on whole blood or serum, ELISAs performed
on saliva appeared to be more than 90% sensitive and
speciﬁc for the detection of trypanosome-speciﬁc antibodies
in the saliva [43–45]. Contrarily to CATT which cannot
be successfully performed with saliva due to its insuﬃcient
analytical sensitivity and the occurrence of unspeciﬁc agglu-
tination reactions, ELISA presents the advantage of a high
speciﬁcity [38]. Unfortunately, ELISA is not applicable for
mass screening of the population at risk in sub-Saharan
Africa rural areas, as this technique requires large volumes
of pure water, pipettes, and many secondary antibodies and
conjugates that are not stable at ambient temperatures [46].
Besides, the test takes a few hours [45].
Overall,thereisstillnoaccurateserologicalscreeningtest
for T.b. rhodesiense infection in the ﬁeld, where the same
tests used for T.b. gambiense are used with less accurate
results, and unfortunately, there is no promising laboratory
breakthrough to solve this problem. On the other hand,
powerful molecular techniques have been successfully tested
for the diagnosis of T.b. gambiense HAT. However, up to
now, many of these techniques still need to be modiﬁed and
adapted to ﬁeld conditions in order to reach the patients.
The development of simple and standardized tests applicable
to ﬁeld conditions from these ﬁndings is considered [33].
3.StagingandPosttreatmentFollowup
As previously stated and discussed in Section 2, the drugs
used to cure the HAT ﬁrst stage poorly cross the BBB, and
other drugs, which are far more toxic, are used to cure stage
2 patients. Therefore, after HAT diagnosis, the disease stage
determination is a crucial step to decide the treatment to4 The Scientiﬁc World Journal
administer. After treatment, patients must be followed up to
early detect and cure the relapses.
3.1. Who Criteria. The commonly accepted criteria in
used in the ﬁeld for HAT staging are from 1998 WHO
recommendations [47] modiﬁed in 2006 [31]. According
to these recommendations, HAT stage 2 is marked in
the CSF by the presence of trypanosomes, by alterations of
the total protein level (diﬀerent cutoﬀs have been proposed
and vary from 250 to 450mg/L), and by elevated white
blood cell (WBC) counts (cut-oﬀsa r eS t a g eI< 5 cells/μL,
“intermediate” stage with 5–20 cells/μL, early Stage II at 20
cells/μL) [22, 38]. The study of cells in the CSF of HAT
patients for disease staging was justiﬁed by the postmortem
ﬁndings [10]. However, WHO cut-oﬀ criteria seem to have
been decided arbitrarily, resulting in malfunction of these
criteria in the ﬁeld [48]. Overall, these criteria are debated
[7, 11, 17], and African trypanosomes are rarely found in
the CSF of patients, even in the late HAT stage 2 [32, 48].
For posttreatment followup, WHO recommends that
treated HAT patients be followed for up to 2 years before
a decision on treatment outcome can be taken [49]. Treated
patients’ blood and CSF are to be examined every 6 months
[22, 43]. However, due to the generally low sensitivity of
the available parasite detection tests, a substantial number
of relapsing patients is not detected early and thus not
given treatment. This results in prolonged suﬀering and even
death of patients and also has major consequences at the
communitylevel,becauseinfectedpeopleactasreservoirsfor
T.b. gambiense [25]. Additionally, many patients are afraid of
lumbar puncture and as soon as they feel better, they cease
coming to follow-up appointments [17, 23].
Therefore, less invasiveness and better criteria for disease
staging are needed, considering the importance of such cri-
teria for the treatment and followup of patients. Less invasive
and sensitive diagnostic tools are also needed for disease
severity monitoring for relapses detection and management.
3.2. ProposedMarkersandToolsforHATStagingandFollowup
3.2.1. Inﬁltrating Inﬂammatory Cells. Knowledge about the
inﬂammatory cells inﬁltration and brain damage in HAT
originates mostly from animal studies, as only a few clinical
studies reporting observations on deceased HAT patients
have been published [10]. In T.b. gambiense-infected vervet
monkeys, perivascular cuﬃng, meningitis, and encephalitis
have been described, with inﬂammatory inﬁltrate comprised
mononuclear cells, lymphocytes, plasma cells, and Mott cells
[50]. In this model, as well as in T.b. rhodesiense-infected
mice and in T.b. gambiense-infected rats, trypanosomes
appeared to spread together with inﬂammatory cells, being
ﬁrst located in the choroid plexus, then spreading to
the perivascular space and ﬁnally to the brain parenchyma,
resulting in a triphasic meningoencephalitic inﬂammatory
disease [51, 52]. The 3 phases which have been envisaged are
(i) a chronic meningitis with plasma cells, lymphocytes, and
monocytes in the subarachnoid and pial connective tissue,
(ii) a progressive neuroinﬂammation from the meninges to
the cerebral vessels entering the brain, and (iii) the develop-
ment of encephalitis.
Overall, the human post-mortem material examination
has revealed a pattern of neuroinﬂammation similar to that
observed in animal models though with some diﬀerences
in the severity of inﬂammatory reaction features [21].
The hallmark of CNS pathology in autopsies of HAT fatal
cases is a generalized meningoencephalitis with marked
cellular proliferation seen in the leptomeninges together
with diﬀuse perivascular inﬁltration of white matter with
lymphocytes, plasma cells and macrophages, and activated
macrophagesandastrocyteswithintheperivascularcuﬀsand
adjacent parenchyma [53].
To enter the brain parenchyma, T.b. as well as WBC cross
the BBB. This physical barrier situated between the lumen
of the cerebral blood vessels and the brain parenchyma
is formed by tight junctions of the endothelial cells of
blood vessel walls surrounded by basement membrane and
astrocyte endfeet [54, 55]. To cross the BBB and enter
the brain parenchyma, leukocytes establish loose connec-
tions with endothelial cells via selectin-integrin interactions,
which allow them to roll along the endothelial cell barrier
with the ﬂowing blood. Leukocyte transmigration occurs
in response to the presence of surface-bound luminal
chemokines following a chemotactic gradient. If these
chemokines are ﬁxed by leukocyte chemokine receptors, sig-
naling pathways within the leukocyte are activated resulting
inconformationalchangesintheleukocyteintegrins,leading
to high-aﬃnity binding to the endothelial cell via adhesion
molecules.Thentheleukocytesmovetothe inter-endothelial
junction, and through that junction, they extend protru-
sions, sampling for abluminal chemokines. After crossing
the endothelial cell layer, leukocytes are sequestered in
the perivascular space between the endothelial cell base-
ment membrane and the parenchymal basement membrane.
For the completion of the transmigration into the brain
parenchyma,thedegradationofthecellularmatrixbymatrix
metalloproteinases is needed [56, 57].
In the presence of elevated amounts of the proin-
ﬂammatory cytokine tumor necrosis factor-(TNF-)alpha,
the binding of leukocytes to cellular adhesion molecules
and their transmigration across the blood-CSF barrier are
increased [58]. This cytokine level is high all over the course
of African trypanosomiasis, and this ﬁnding could explain at
least part of the observations made on the brains of deceased
HAT patients. On this basis, studies were recently performed
in the blood and CSF of T.b. gambiense HAT patients in
Angola and Gabon to determine the number and types
of leukocyte immunophenotypes present along the disease
course. From this studies emerged that the number of B cells
intheCSFcouldbeagoodindicatorofHATstageanddisease
severity [59]. Other studies, on basis of the investigation of
the CSF from T.b. gambiense patients at diﬀerent stages of
infection,havealsosuggestedtheamountofBcellinthe CSF
as indicator of HAT stage and severity [60]. Even if the
application of this approach would still require the invasive
and “frightening” lumbar puncture, B cells rosettes are
easily detected in ﬁeld conditions [60] and would therefore
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3.2.2. Inﬂammatory Mediators. The precise mechanisms by
which T.b. enter the brain and how this parasite and the
inﬁltrating inﬂammatory cells interact between them and
with resident cells to produce the alterations resulting in the
speciﬁc meningoencephalitis observed in African trypanoso-
miasis are still to be unraveled. However, the proinﬂam-
matory cytokine interferon- (IFN-) gamma is likely to play
a critical role for the traversal of the BBB by T.b. [61, 62].
Numerous studies in animal models indicate that the
expression of inﬂammatory mediators (cytokines, chemok-
ines, and adhesion molecules) change with the course of the
infection, with a central role played by the balance between
pro- and anti-inﬂammatory mediators in the outcome of
the disease (see Kristensson et al., 2010 for review). Findings
have pointed to an association between cytokine expression,
particularly IFN-gamma and TNF-alpha, and the onset
and development of the neuroinﬂammatory reaction. The
CSF levels of the chemokines CXCL-2, CCL-5, CCL-3, and
CCL-2 have been reported to increase in the brain early after
infection; the early source of these inﬂammatory mediators
appeared to be the brain resident cells astrocytes and
microglia, with T cells and macrophages taking the pro-duc-
tionoverlaterduringthediseasecourse[10,63].Thisﬁnding
suggests that the initial steps in the development of the neu-
roinﬂammatory disease are controlled from within the CNS.
Such factors may be responsible for initiating inﬂammatory
cell and T.b. inﬁltration to the brain parenchyma, that is, the
beginning of African trypanosomiasis stage 2 [51].
In contrast to the cytokine proﬁles derived from rodent
models, no signiﬁcant changes in TNF-alpha or IFN-gamma
CSF concentrations were reported in humans [43, 64].
Such a discrepancy could reﬂect either divergences between
the cytokines present in the brain and the CSF, or variations
in the sensitivity of the assay systems used [51].
In terms of clinical data, a correlation between IFN-
gamma concentration in the plasma and disease progression
in the CNS has been shown in HAT patients in Uganda
(T.b. rhodesiense), but no signiﬁcant changes were found in
CSF levels of TNF-alpha or IFN-gamma [64, 65]. In the CSF
of these patients were also found signiﬁcant increases of




serum/CSF concentration quotients indicated an intrathecal
synthesis of IL-10 in 29% of patients [65, 66].
On the basis of the hypothesis that brain damage
and inﬂammation-related proteins could individually or
in combination indicate the CNS invasion by T.b.,m a n y
studies aiming at the determination of markers for eﬃcient
discriminationoftheHATstageshavebeenrecentlysearched
in the CSF by proteomic analyses. CSF samples from T.b.
gambiense patients, diagnosed on the basis of CSF WBC
counts and presence of parasites, have been used to study the
levels of 3 brain damage-related proteins (H-FABP, GSTP-
1, overexpressed in post-mortem CSF, and S100b, marker
of BBB and neuronal damage) and 13 inﬂammation-related
proteins (IL-1-alpha, IL-1-beta, IL-6, IL-9, IL-10, G-CSF,
VEGF, IFN-gamma, TNF-alpha, CCL2, CCL4, CXCL8, and
CXCL10). The ﬁndings indicated that CXCL10 could distin-
guish stage 1 from stage 2 patients, with a sensitivity of 84%
and 100% speciﬁcity, and a panel characterized by CXCL10,
CXCL8,andH-FABPwasdeﬁnedtoimprovethedetectionof
HAT stage 2 patients [48] .T h e s ea n a l y s e sw e r epe rf o rm e do n
a relatively limited sample of patients from the same cohort,
and still are to be validated in a larger multicentric cohort,
but other experimental evidence from animal models and
HAT patients conﬁrmed these ﬁndings [67, 68].
4.TreatmentandVaccineDevelopment
4.1. Presently Available Drugs. Four trypanocidal drugs are
mainly in use in the ﬁeld: pentamidine and suramin,
which are eﬃcient in the early stage of the disease, and
melarsoprol and eﬂornithine, which are eﬃcient in the late
stage. The ﬁeld drugs, particularly those used in the second
stage of the disease, have severe side eﬀects and may even be
fatal [14, 32, 69, 70].
4.1.1. Suramin. Pioneering work of the German researcher
PaulEhrlich(1854–1915),winneroftheNobelPrizeinPhys-
iology or Medicine in 1908, demonstrated that naphthalene
dyes, trypan red, and trypan blue have trypanocidal activity
due to selective accumulation by trypanosomes. Following
Ehrlich’s observations, suramin, a colorless polysulphonated
symmetrical naphthalene derivative drug, was developed in
the 1920s [71]. This drug has also been used against the
ﬁlarialparasiteOnchocercavolvulus,andtrialsagainsthuman
immunodeﬁciency virus, and other human viruses, and
against diﬀerent types of cancer have been performed [72,
73].Atypicalprotocolof5slowintravenousinjections,every
3–7 days, over a 4-week period, is used to cure HAT [14, 69].
The trypanocidal action of suramin is still unclear, and
many hypotheses have been proposed. (i) Suramin could
impede uptake of serum proteins or inhibit endocytosis
and key enzymes in metabolic pathways such as glycolysis
thanks to its negative charge and the chemical properties
derived [74]. Thus, suramin could act by the formation
of complexes with LDL impeding the receptor-mediated
uptake of LDL, carrier of cholesterol required for parasite
growth. (ii) Suramin could accumulate inside the lysosomes
and inhibit some key enzymes such as 3 -nucleotidase or
protein kinase (which both bind to the plasma membrane
of the trypanosome), acid phosphatase or acid pyrophos-
phatase (in the ﬂagellar pocket), or phospholipase A1.
(iii) Suramin could also inhibit the high positive-charged
glycolytic enzymes located inside the glycosome on the
African trypanosomes [69, 75].
AsAfricantrypanosomesareunabletosynthesizedenovo
fatty acid and cholesterol, the development of resistance to
suramin in the ﬁeld is unlikely considering the important
role of LDL in the growth and proliferation of these
parasites [69, 75]. However, reports of treatment failures
from foci of the Gambian form of HAT in the 1950s led
the use of this drug mainly for the Rhodesian form of HAT
[14]. In veterinary use, resistance has been noted in some
trypanosomespecies,suchasT. evansi [76].Themechanisms
of resistance are still to be unraveled.6 The Scientiﬁc World Journal
A considerable amount of suramin binds to serum
proteins, and consequently, the suramin half-life in serum
is very long (44–54 days in the study of Collins et al.,
1986). Although HAT regimens are considered short enough
to oﬀer safety and tolerability, the US Food and Drug
Administration blocked the approval of suramin for use in
prostate cancer because of the adverse eﬀects reported [69].
4.1.2. Pentamidine. Pentamidine (1,5-bis (4-amidi-phenox-
ypentane]) is a diamidine, that is, an aromatic diamine,
which has been used for several decades in the chemotherapy
of African trypanosomiasis, leishmaniasis, and against Pneu-
mocystis carinii pneumonia in acquired immunodeﬁciency
syndrome patients [69].
As for suramin, the pentamidine mode of trypanocidal
action remains uncertain. Overall, diamidines act directly
against the parasites independently of their physiological
action against the host, and the transport of these drugs
across the cell membrane is a necessary ﬁrst step to antipar-
asitic action [69, 70]. The trypanosomes accumulate large
amounts of pentamidine via P2 aminopurine permease [77].
In trypanosomatids of the Leishmania species, close relatives
of trypanosomes, ﬂuorescent analogues of pentamidine have
been shown to accumulate mostly in the mitochondria
resulting in the permanent damage of these organelles
and cell death [78, 79]. In addition, in Leishmania, the
pentamidine resistance correlates with a reduction in the
mitochondrial membrane potential [80, 81]. This is due
to the fact that pentamidine interacts electrostatically with
cellular polyanions, binding DNA including the kinetoplast.
This latter organelle is a characteristic of kinetoplastid ﬂag-
ellates and is constituted by a unique intercatenated network
ofcircularDNAmoleculeswhichmakeupthemitochondrial
genome [82, 83]. However, whether the localization of
ﬂuorescent analogues of pentamidine correlates with activity
is not certain, and, in addition, the mammal bloodstream
form of T.b. can survive kinetoplast DNA disintegration
[84].
A high-aﬃnity and a low-aﬃnity pentamidine trans-
porter(HAPT1andLAPT1,resp.)contributetopentamidine
uptake. These transporters explain, at least in part, the
eﬃcacy of this drug also against melaminophenyl arsenical-
resistant parasites that lack the P2 transporter [70, 79]. A
retained activity of the P2 transporter has been shown in an
African trypanosome laboratory line selected for pentami-
dine resistance [69, 77]. Furthermore, lack of HAPT1 trans-
porter has been observed in another pentamidine resistant
line also lacking the P2 transporter [85]. On this basis, it has
been suggested that the resistance to pentamidine may be
due to the lack of pentamidine transporters [14]. However,
as these pentamidine-resistant lines displayed much reduced
virulenceinrodentmodels,ithasalsobeensuggestedthatthe
development of resistance to pentamidine is associated with
substantial ﬁtness costs, therefore rendering the propagation
of resistant lines in the ﬁeld unlikely [14, 70].
4.1.3. Melarsoprol. The mechanism of action of the arsenical
compound melarsoprol has been recently reviewed [13, 86].
This drug is still the most widely used to cure the late stage
of HAT despite its extremely toxic side eﬀects [14], as it is the
only drug eﬀective in the second stage of the Rhodesian form
of HAT, and as it is far less expensive than the other drugs
used in the second stage of Gambian form of the disease [22,
31, 76].
The uptake of melarsoprol in the trypanosomes is
accomplished by purine transporters, as this drug acts as a
competing ligand for the purine site on the transport protein
[14]. Purine transport is highly developed in trypanosomes
as they directly acquire nucleic acids from their hosts. The
trypanosomes lyse rapidly when exposed to melarsoprol
[87]. T.b. thiol-containing enzymes (such as glycerol-3-
phosphate dehydrogenase) could be the targets of melarso-
prol, as it has been reported that trypanocidal analogues of
this drug (such as cymelarsan used to treat nagana) bind
strongly to these enzymes [88]. Functional alterations of
these enzymes could underlie the lysis of trypanosomes, as
they lead to inhibition of glycolysis, and therefore to the loss
of ATP, although these cells seems to lyse before ATP supplies
are seriously depleted [14, 87].
The active metabolites of melarsoprol contain a trivalent
arsenic element with a markedly reactive arsenoxide group,
which confers the physicochemical ability of lipid solubility
that allows the passage of the drug across the BBB [89,
90]. In addition to this transport function, the arsenoxide
group probably mediates the killing of trypanosomes in
the cerebrospinal ﬂuid (CSF). This is suggested by the fact
that modiﬁcations of the melarsoprol parent ring have a
signiﬁcant impact on its trypanocidal action. The trivalent
derivatives of melarsoprol, such as melarsen oxide and
phenylarsine, are highly active even in relatively low con-
centrations,whileitspentavalentderivativesareconsiderably
less active, and its nonarsenical chemical constituents are
completely inactive against T.b. [69, 88].
Melarsoprol was introduced to replace tryparsamide,
anotherarsenical, and the drug regimens werenot supported
by pharmacokinetic studies [91]. After recent assessment of
pharmacological properties and proﬁle of melarsoprol, the
treatment schedule has been improved. Much of the drug
has been found to bind to plasma protein with a mean
serum half-life of active metabolite of 3.5–3.8h and a very
slow elimination time from the CSF with a half-life of 120h
[92]. The drug regimen used nowadays is a standardized
10-day course with 2.2mg/kg once a day instead of 3 series
of 4 intravenous injections (at a dose of 3.6mg/kg), with
i n t e rvalo f1 0d a y sbetw ee neac hse ri es,asp r evi o usl yad o pt ed
[32, 89]. This drug regimen reduces drastically the time of
exposure to melarsoprol but fails to show improvements of
the severe side eﬀects of this drug, particularly the lethal
reactive encephalopathy [93].
In the ﬁeld, failures of HAT treatment with melarsoprol
have reached 30% of the treated cases in several foci [21,
22]. Most parasites selected for resistance to melamine-
based arsenicals in the laboratory and several parasites
isolated from relapse cases in the ﬁeld have been shown
to have lost the P2 aminopurine transporter [14, 87].
However, trypanosomes from which this transporter has
beenremovedareonlymarginallylesssensitivetomelamine-
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suggests the existence of secondary routes of uptake and
indicates that the loss of P2 transporter must be coupled
with the loss of these secondary routes for high-level
resistance [14]. Melarsoprol resistance has also been shown
in trypanosomes with ectopic overexpression of the tbmrpa
gene that encodes a P-glycoprotein type pump [14].
4.1.4. Eﬂornithine. Eﬂornithine (D,L-a-diﬂuoromethylor-
nithine) is an analogue of the amino acid ornithine ﬁrst
developed as a potential antineoplastic agent [14]. This drug
is eﬃcient against T.b. gambiense but not T.b. rhodesiense
[31].
Eﬂornithine has similar aﬃnity for both the mammalian
and trypanosomal polyamine biosynthetic enzyme ornithine
decarboxylase (ODC) and acts as an inhibitor of this enzyme
[95]. T.b. gambiense ODCs are degraded and replenished
much more slowly than in the mammalian counterpart, and
therefore, eﬂornithine deprives trypanosomes of polyamine
synthesis for a prolonged period compared with mammalian
cells. This polyamine biosynthesis inhibition is accompanied
by an increase in cellular levels of S-adenosyl methionine,
which causes inappropriate methylation of proteins, nucleic
acids, lipids, and other cell components [14, 95, 96]. At
variance with T.b. gambiense, T.b. rhodesiense present a rapid
turnover of that enzyme, rendering eﬂornithine noneﬀective
against this parasite [97]. A diminution of trypanothione
levels was also observed after eﬂornithine treatment [14, 98],
and this may increase the susceptibility of T.b. gambiense to
oxidative stress and other immunological insults.
Eﬂornithine passive diﬀusion across the plasma mem-
brane was proposed to account for the uptake of eﬂornithine
in both bloodstream forms of T.b. [99]e v e ni fe v i d e n c ef r o m
genomic studies suggests the presence in T.b. of genes encod-
ing amino acid transporters which could carry eﬂornithine
[100, 101]. Doses beyond 100mg/kg of eﬂornithine given per
os fail to increase the drug level in the plasma, suggesting that
the drug is accumulated by a saturable transporter [102]. It
is also probable that a transporter carries the drug across
the BBB, from where the “y system” (the more important
cationic amino acid transport system in mammals) takes
over [102, 103].
Little serum protein binding of eﬂornithine occurs,
and, accordingly, the mean half-life in plasma following
intravenous injection of eﬂornithine is about 3-h, with up to
80%ofthedrugexcretedunchangedinurineafter24h[104].
Thus, the drug regimen is very fastidious, as large doses are
given by prolonged intravenous infusion [22, 32].
Eﬂornithine resistance of T.b. procyclic forms has been
shown to be related to a reduction of drug uptake [99, 105],
suggesting that resistance could be related to loss or changes
of eﬂornithine transport into cells.
4.2. New Combination Therapy and Drugs in Clinical Trial
4.2.1.Nifurtimox-EﬂornithineCombinationTherapy(NECT).
Nifurtimox is a drug used to treat another trypanosomal
illness, Chagas disease or American trypanosomiasis caused
by T. cruzi. The organization “Medecins Sans Fronti` eres” has
conducted 2 sequential clinical drug-combination studies at
HAT treatment sites in northern Uganda from 2001 to 2004,
which have reported that NECT is highly eﬀective and well
tolerated [76, 79]. NECT was added to the “WHO Essential
Medicines List for the treatment of second-stage Gambian
HAT” in April, 2009, on the basis of key advantages over the
previous therapeutic options such as high eﬃcacy and good
safety proﬁle consistently observed [6].
NECT is easier to administer, requires fewer human and
materialresourcescomparedwitheﬂornithinemonotherapy,
and currently stands as the most promising ﬁrst-line treat-
ment for second-stage Gambian HAT [106]. NECT requires
14 intravenous infusions of eﬂornithine over 7 days and oral
administration of nifurtimox 3 times per day for 10 days,
while eﬂornithine monotherapy requires 56 intravenous
infusions over 14 days [76, 106]. However, the training needs
forNECTarestillconsiderableintreatmentcentersthathave
not yet used eﬂornithine [106].
NECT has been suggested to be less susceptible to gen-
erate parasitic resistance, as this treatment strategy combines
two drugs with diﬀerent modes of action [13].
4.2.2. Diamidines. Several thousands of diamidine deriva-
tives with a broad range of trypanocidal activity and sur-
prisingly diverse pharmacokinetic proﬁles have been devel-
oped [13]. One of these derivatives approved by the US
FDA for the treatment of Pneumocystis jiroveci pneumonia,
pafuramidine (DB289), demonstrated equal eﬃcacy and less
overt toxicity with/than pentamidine in a multicenter phase
3 trial involving 273 HAT patients.
Interestingly, some aza analogs of DB289 have shown
similar in vitro proﬁles against diﬀerent T.b. strains, melar-
soprol-andpentamidine-resistantlines,andaP2transporter
knockout strain (AT1KO) [107]. Some of these compounds,
as DB75, show a higher trypanocidal activity [108], and
others as DB868 have been reported not only to kill the
trypanosomes in the peripheral organs and in the blood
compartment, but also, interestingly, to cross the BBB in
levels suﬃcient to kill trypanosomes in the HAT stage 2
mouse model, suggesting eﬃciency in both stages of the
infection [107, 109]. CPD-0802, a compound of this group,
is currently under consideration for clinical development for
stage 2 HAT [13].
4.2.3. Nitroheterocycles. The discovery in T.b.m e t a b o l i s mo f
an unusual bacterial type 1 nitroreductase enzyme capable
of the reductive activation of nitro compounds, that is not
found in mammals [74], has “added impetus to the quest as
did the introduction of novel nitroheterocycles into clinical
trials for tuberculosis, anaerobic protozoan and helminth
infections” [13]. Among the numerous compounds tested,
fexinidazole showed to be eﬃcient with oral dosing in
the mouse model of stage 2 HAT, and the drug proved
be metabolized to trypanocidal sulphoxide and sulphone
metabolites. In 2009, fexinidazole entered the phase I clinical
trials which are presently ongoing [13].
4.3. Emerging Challenges for Vaccine Development. The
emerging challenges for the development of a vaccine8 The Scientiﬁc World Journal
against African trypanosomiasis were recently reviewed [29,
110], and in this section, they will be brieﬂy discussed.
The cell surface of the procyclic and epimastigote forms
of T.b. (found in the ﬂy) is covered with an invariant
glycoprotein coat composed of about 10 million copies of
two isoforms of a protein named procyclin. These isoforms,
named accordingly to their amino acid repeats in their C-
termini,areEP-procyclin(whichhas22–30Glu-Prorepeats),
and GPEET-procyclin (which has 5-6 Gly-Pro-Glu-Glu-Thr
repeats followed by 3 EP repeats), [4, 111]. Both protein
isoformsareattachedtothemembraneviaGPIanchors[112,
113]. When epimastigotes diﬀerentiate into the metacyclic
form (the form inoculated by the ﬂy), the EP-procyclin and
GPEET-procyclin coat is replaced by about 10 million copies
of a single VSG. Once in the host bloodstream, the parasite
keeps the metacyclic VSGs for up to 7 days and then switches
to the expression of nonmetacyclic VSGs [112, 114]. In
the bloodstream parasites, about 1,000 genes are coding for
VSGs [115], thanks to which African trypanosome species
escapetheimmuneresponseofthehostsbyreadilyswitching
their surface coat, sequentially expressing diﬀerent forms
of VSG at a rate of 10−2 to 10−7 switches/doubling time
of 5−10h [4, 113, 116]. Such escape mechanism conﬁrms
the adaptation of the parasite to its hosts and constitutes
the main diﬃculty for the development of a vaccine against
African trypanosomiasis and also because of the incomplete
understanding of the control and execution of this immune
evasion strategy in trypanosomes [114, 117, 118].
The VSG coat challenge has led to the question of
the development of a non-VSG-based vaccine. African try-
panosomes express numerous nonvariable surface antigens.
In the recent years, many non-VSG candidates have been
used for experimental vaccination schemes for trypanosomi-
asis; most reports prove promising, but not a single strategy
was eﬀective enough for the development of an eﬀective
vaccine [110]. Of particular interest has been the ﬂagellar
pocket, an organelle specialized in endocytosis and exocyto-
sis containing relatively well-conserved receptors [119], and
cytoskeleton proteins, as an interesting group of nonvariable
antigens[120].Themainpitfallthatmightexplainthefailure
of all these strategies was suggested to be the fact that
immunization against these proteins might never result in
signiﬁcant B cell memory-based protection in experimental
model systems that are characterized by an excessively high
parasite burden early on in infection, as most of the models
used up to know for vaccine development [110]. In order
for a vaccine targeting trypanosomes to act, it should have
the ability to eliminate all circulating trypanosomes before
they trigger mechanisms of B cell memory suppression or
destruction [45]. Thus, these parasites seem, up to now,
to have always been able to modulate the B cell memory
response in their advantage, impeding the B cell response
that aims to eliminate them, rendering further more diﬃcult
the realization of a vaccine.
Interestingly, a positive note derives from research
attempting another approach: the development of vaccines
aimed to reduce T.b. transmission through immunization
against insect parasite stages which express an invariant
glycoprotein coat, that is, blocking the parasitemia onset in
the host, as the successful antitick vaccine [110]. Several
antigens have been already proposed as candidates for
such experimental vaccination schemes and are being tested
[110].
5. The Potentialof MedicinalPlants in
TrypanosomiasisManagement
5.1. Medicinal Plants as Alternative Drugs. Interest in higher
plant extracts exhibiting antimicrobial activity has increased
in recent years, and several reports on this subject have been
published. Indeed, the use of and search for drugs derived
from plants have accelerated in recent years [121–128],
whereby ethnopharmacologists, botanists, microbiologists,
and natural-product chemists are combing the earth for
phytochemicals and “leads” which could be developed
for the treatment of various ailments. WHO has esti-
mated that 80% of the population of developing countries
relies on traditional medicines, mostly plant drugs, for
their primary health care needs [129–132]. For instance,
the use of herbs and medicinal plant products has become
a mainstream phenomenon over the past two decades in
many countries, where herbs and phytomedicines (herbal
remedies) have become one of the fastest growing segments
in retail pharmacies and supermarkets [121, 128]. It is of
no denying that medicinal herbs now constitute the most
rapidly growing segment of the total US pharmaceuti-
cal market and are now used by approximately 20% of
the population [133, 134]. Available reports tend to show
that about 25% of all prescriptions sold in the US are from
natural products, while another 25% are from structural
modiﬁcations of a natural product [134, 135]. In other
reports [136, 137], it is proposed that 3 in 10 Americans
use botanical remedies in a given year giving rise to
a whole new industry referred to as “nutraceuticals” and
currently,20,000herbalproductsareavailableinthiscountry
[134, 138].
Indeed, it is clear from available literature that modern
pharmacopoeia still contains at least 25% drug derived from
plants, and many others, which are synthetic analogues,
built on prototype compounds isolated from plants [125,
135]. Despite the availability of diﬀerent approaches for
the discovery of therapeuticals, natural plant products still
remain as one of the best reservoirs of new structural types.
Concurrently, many people in developing countries have
begun to turn to alternative therapies as cheap sources
of complex bioactive compounds and evidence of the
beneﬁcial therapeutic eﬀects of these medicinal herbs is
seen in their continued use [124, 127, 134, 139]. The
importance of medicine of natural product molecules lies
not only in their pharmacological or chemotherapeutic
eﬀects, but also in their role as template molecules for the
production of new drug molecules. It is of no denying
that knowledge gained from the use of medicinal herbs
and their active ingredients has served as the foundation
for much of modern pharmacology, and many modern
drugs have their origin in ethnopharmacology. Additionally,
the development of modern chemistry has permitted the
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served as drugs or starting materials for the synthesis of
many important commercially important drugs used today
[139, 140]. Drugs such as aspirin, digitalis, morphine, met-
formin, and quinine amongst others were all originally iso-
lated or synthesized from materials derived from plants
[122, 141].
Medicinal plants, unlike pharmacological drugs, com-
monly have several chemicals working together catalyti-
cally and synergistically to produce a combined eﬀect that
surpasses the total activity of the individual constituents.
The combined action of these substances increases the
activity of the main, medicinal constituent by speeding up
or slowing down its assimilation in the body. Secondary
substances from plant origins might increase the stability
of the active compound(s) or phytochemicals, minimize
the rate of undesired side eﬀects, and have an additive,
potentiating, or antagonistic eﬀect [125, 126].
With the exception of antimalarials and as mentioned
above, there are currently only four drugs approved to treat
HAT. However, eﬂornithine and pentamidine are ineﬀective
against sleeping sickness caused by T.b. rhodesiense.T r e a t -
ment with melarsoprol, the only generally eﬀective ﬁrst-line
drug, required lengthy parenteral administration and can
result in up to 10% mortality. Additionally, the toxicity and
the upsurge in the number of patients failing to respond
to melarsoprol because of drug resistance reﬂects the need
for discovery of new chemotherapeutic agents against HAT
[142]. To this eﬀect, the insuﬃciency of current therapies
for the treatment and management of trypanosomiasis,
combined with both a lack of trust in conventional medical
treatment and an inability of the economy to absorb the cost
of pharmaceuticals, have created a growing public interest in
alternative natural drugs from botanicals.
5.2. Phytotherapy for HAT. Drug-screening activities from
plants have started decades back, and an emerging number
of studies have now been developed and reported so far to
discoverdrugsfrommedicinalplantsthatcanhelptocombat
trypanosomiasis. The main aim has been geared towards
alternatives to conventional drugs with fewer side eﬀects but
greater eﬀectiveness.
A plethora of studies has been conducted to investigate
the eﬀect of some traditionally used medicinal plants in
alleviating the cellular changes in vivo produced during
the T.b. brucei infections of rats. Traditional knowledge
was the basis for the selection of plants, and one study
included Momordica balsamina pulp, Aloe vera pulp, Annona
senegalensis,Securidacalongipenduculataroot, and root bark.
On the basis of folk medicines, they were claimed to possess
antiprotozoal activity and alleviate one or many of the
clinical symptoms such as intermittent fever, immunosup-
pression, anemia, jaundice, and hepatomegaly commonly
associated with trypanosomiasis. Interestingly, it was found
that these plants had the potential in the management of
HAT due to the fact that T.b. brucei. Momordica balsamina,
and S. longipenduculata were found to possess the highest
potential, since they are able to control anemia by resisting
sudden drop in packed cell volume values [143].
In another study, it was showed that the extracts of
Hymenocardia acida stem bark exhibited signiﬁcant try-
panocidal activity, whereas Gardenia erubescens and Lophira
lanceolata were eﬀective at minimum inhibitory concentra-
tion (MIC) of 20mg/mL [144]. Nigerian plants were also
evaluated in vitro for trypanocidal activity against T.b. brucei
and T. congolense at concentrations of 4mg/mL, 0.4mg/mL,
and 0.04mg/mL. It was found that extracts of Khaya sene-
galensis, Piliostigma reticulatum, Securidaca longepeduncu-
lata,a n dTerminalia avicennoides were strongly trypanocidal
to both organisms while extracts of Anchomanes diﬀormis,
Cassytha spp, Lannea kerstingii,Parkia clappertioniana,Striga
spp, Adansonia digitata,a n dProsopis africana were try-
panocidal to either T.b. brucei or T. congolense. Kigelia
africana, from Kenya, was also evaluated in vivo, and it was
found that the dichloromethane fruits extract of K. africana
tested at a dose of 2000mg/kg was eﬀective, curing 60% of
the Swiss white mice that had previously been inoculated
with T.b. rhodesiense KETRI 3798 [145, 146].
Inanotherinvestigation,Scopariadulciswasevaluatedon
the population of immune cells during a 28-day experimen-
tal T. brucei infection in rabbits. The result obtained showed
thatinfectionresultedinaninitialriseinbothtotalWBCand
the absolute number of circulating lymphocytes followed
by a progressive decrease in total WBC and all WBC sub-
types (lymphocytes, monocytes, and granulocytes) although
the percentage of lymphocytes remained consistently higher
than normal throughout the study period. These changes
were consistent with the development of trypanosome-
induced immunosuppression in their mammalian host, and
interestingly, treatment with S. dulcis at a daily oral dose
of 25mg/Kg body weight was found to signiﬁcantly reduce
the severity of the observed lesions when compared with
untreated infected animals. Thus, S. dulcis was classiﬁed as
a potential herb that had demonstrated signiﬁcant potency
in protecting against the parasite-induced decrease in the
population of immunologically active cells [147].
From the above key investigations, it is clear that these
ﬁndings provide strong evidence of the potential beneﬁcial
eﬀectsofphytotherapyinthetraditional managementoftry-
panosomiasis which could be subsequently developed into
a cost-eﬀective alternative drug to complement treatment of
trypanosomiasis.
5.3. Possible Mechanism of Phytochemicals against Trypanoso-
miasis. Inmanyinvestigationsconductedsofar,itwasfound
that the plant parts diﬀer signiﬁcantly in their activity.
The diﬀerencesobservedintheantimicrobialevaluationsug-
gest the susceptibility of the test microorganism to various
secondary metabolites present in these medicinal plants. In
general, discussions pertaining to anti-Trypanosoma agents
from plants center on plant secondary metabolites, that is,
nonubiquitous constituents with no known essential role
in the plant’s metabolism. However, it has been postulated
that bioactive plant secondary metabolites may play a role
in chemical defense mechanisms and are likely molecules for
the antiparasitic agents in these plants [125, 126].
Recently, it has been postulated that the enormous diver-
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products but specialized secondary metabolites involved in
the relationship of the organism with the environment,
for example, as attractants of pollinators, signal products,
defensive substances against predators and parasites, or in
resistance against pests and diseases [140]. Indeed, the com-
position of these secondary metabolites in turn varies from
species to species, climatic conditions, and the physiological
state of developments of the endemic plants [148]. Available
reports tend to show that alkaloids and ﬂavonoids are the
responsible compounds for the antimicrobial activities, and
anti-Trypanosoma in higher plants [149]. Moreover, it is
also claimed that secondary metabolites such as tannins and
other compounds of phenolic nature are classiﬁed as active
antimicrobial compounds [150, 151].
Nonetheless, several investigations tend to suggest that
it is often diﬃcult to speculate and decipher the exact
mode of action by which these plants extracts exhibit their
trypanocidal action. Indeed, the possible mechanisms by
which these plants extracts and phytochemicals therein
carry out this role remain a subject of great speculations
and debate in the scientiﬁc community. Several possible
mechanisms working separately or in concert may account
for the observed eﬀect [147].
I no n es t u d y ,i tw a ss u g g e s t e dt h a td i ﬀerent phyto-
compounds could be responsible and operate in a syn-
ergistic eﬀect for the observed antitrypanocidal activities.
Interestingly, preliminary phytochemical screening of potent
plants against trypanosome showed the presence of biolog-
ical known active compounds such as saponins, tannins,
ﬂavonoids, and alkaloids in the crude plant extracts tested.
Several authors have also identiﬁed or isolated tannins and
phenolic compounds, ﬂavonoids, and alkaloids in plants that
showed signiﬁcant trypanocidal activities [152].
Accumulated evidence also suggest that many natural
products exhibit their trypanocidal activity by virtue of
their interference with the redox balance of the parasites
acting either on the respiratory chain or on the cellular
defenses against oxidative stress. For instance, the observed
trypanocidal activity of K. africana extract was justiﬁed due
to the increase of oxygen consumption and stimulation
of hydrogen peroxide production in the protozoan cell.
Trypanosoma do not have the same biochemical mecha-
nism as mammalian cells for dealing with excess peroxide
and consequent oxygen free radicals [146]. Furthermore,
it is proposed that natural products possess structures
capable of generating radicals that may cause peroxidative
damage to trypanothione reductase that is very sensitive
to alterations in redox balance. It is also known that
some agents act by binding with the kinetoplast DNA of
the parasite.
On the other hand, the result of [153]h a sc l e a r l y
indicated that diﬀerent solvent extracts of the same plant
may exhibit diﬀerent trypanocidal activity just as extracts of
diﬀerent parts of the same plants. Therefore, the statement
that a plant is trypanocidal or not should be taken within
the context of the solvent used and the parts investigated.
On the other hand, out of the 40 plant extracts tested
by [154, 155], the dichloromethane extract from stem
bark of Warburgia salutaris (claimed to be used against
many pathologies in many parts of Africa) was found
to exhibit the most potent trypanocidal activity. The try-
panocidal activity was suggested to be due to the drimane
sesquiterpenoids (warburganal and polygodial). Concerning
the mechanism, it was proposed that the two sesquiterpene
aldehydes, warburganal and polygodial, formed covalent
bonds with amino groups of proteins and aﬀect a vast
number of cellular activities. In another groundbreaking
in vitro study, the authors were able to isolate the pregnane
glycosides from genus Caralluma (C. Penicillata, C. tubercu-
lata,a n dC. russelliana) and evaluated for the trypanocidal
activity. It was found that the penicilloside E to possess
the highest anti-Trypanosoma activity followed by caratu-
berside C, which exhibited the highest selectivity index
[142].
Studies have shown that it is probable that the etiology of
trypanosome-induced leucopenia in rabbit may be similar to
the case with trypanosome-induced anemia. There has been
striking indications that the onset of anemia in HAT may
be strongly related to disruption of erythrocyte membrane
caused directly by parasite attack on red cells. It has also
been suggested that products secreted by the parasite may
play a signiﬁcant role in the disruption of red cell mem-
brane. Reduction in red cell membrane sialoglycoprotein
secondary to elevated activity of plasma sialidases promotes
the rapid destruction of erythrocytes. A role for parasite
and macrophage-derived free radicals and proteases in the
pathogenesis of trypanosome-induced anemia has also been
postulated [147]. The possibility that S. dulcis or certain
components of the herb may help stabilize the membrane
of blood cells cannot be outrightly dismissed. Speciﬁcally,
it is not out of place to suggest that the antioxidant or
free radical scavenging properties of S. dulcis may play
vital roles in this regard especially against the backdrop of
the role of free radicals in the pathogenesis of T. brucei
infection and also probable that increased production of
blood cells helps in replenishing of these cells. In the
absence of any evidence of possible trypanocidal activity
for the herb, it does not seem an attractive option to
speculate that the higher level of immunological cells in
treated animals could be due to the destruction of the
parasite by agents native to the plant [147]. On the other
hand, [156] have showed that Psidium guajava leaf extract
has trypanocidal properties and has attributed these eﬀects
in parts to the broad antimicrobial and iron chelating
activity of ﬂavonoids and tannins, respectively. They have
also proposed that iron chelation is an eﬀective way of
killing trypanosomes and the prime target is the enzyme
ribonucleotide reductase whose activity is central to DNA
synthesispriortocelldivisionasdepictedintrypanosomiasis
infection.
Moreover, a plant with high in vitro trypanocidal activity
may have no in vivo a c t i v i t ya n dv i c ev e r s ab e c a u s eo f
peculiarities in the metabolic disposition of the plant’s
chemical constituents. Therefore, plants found to be active
in the above-mentioned investigations must be tested in vivo
and tested clinically before a deﬁnite statement can be made
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6. GeneralConclusions
Once neglected, HAT has returned in the center of
the attentions of the scientiﬁc community, resulting in
the recent reversal of the trend of cases which was increasing.
However, as illustrated in Figure 1, studies have shown that
in the last 30 years, HAT cases occurred more often in
countries with conﬂict, high political terror, or civil war,
with an interval as long as 10 years between the start of
conﬂict events and a peak in incidence [12], and considering
that unfortunately, these events still are current in HAT
endemic regions, the risk of future epidemics is consider-
able. Fortunately, a new approach for vaccine development
targeting the insect parasite stages is being tested and bear
higher chances of success than the precedent approaches. In
addition, powerful molecular tools analyzing inﬂammatory
mediators are also proving very eﬃcient for HAT diagnos-
tic staging and followup. Therefore, even if in the ﬁeld,
the problem of proper diagnostic and staging, together with
the posttreatment followup remain the adaptation of such
molecular techniques to ﬁeld conditions that will solve these
gigantic diﬃculties.
The research re-engagement also has produced promis-
ing antitrypanocidal molecules from the diamidine and
nitroheterocycle pharmacological classes which are under
further tests and considered for clinical trials. Prodrugs able
t oc u r eb o t hp h a s e sm a ye v e nh a v eb e e nf o u n d .O v e r a l l ,
developing new drugs to replace the very toxic ones still in
use is crucial, together with more reliable tools for disease
staging and treatment followup. In the ﬁeld, even if only one
drug, eﬂornithine, has been developed in the last 50 years,
a new combination therapy involving that drug and another
one developed for Chagas disease, nifurtimox, is proving a
good replacement forthe highly toxic melarsoprol whichwas
previously the exclusive drug able to cure stage 2 patients.
But this combination of antitrypanocidal drugs appears to
be eﬃcient only against T. gambiense, leaving the treatment
of T. rhodesiense stage 2 patients to the latter arsenic-derived
drug. To this eﬀect, the active principles of traditional
pharmacopoeia and medicinal plants of African countries
have been scrutinized over the past decade as prospective
alternative trypanocides due to less toxicity and side eﬀects.
Indeed, the recent quest for novel anti-HAT pharmacophore
has been geared mainly towards traditional medicines,
local knowledge, and ethnopharmacology. Phytotherapies,
besides their traditional and holistic values, also hold great
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